Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising cost. More than 200 startups are now competing to weave AI directly into research workflows, attracting growing interest from investors. Converge Bio is the latest company to ride that shift, securing new capital as competition in the AI-driven drug discovery space heats up. The Boston- and Tel Aviv–base...